TP53 and prostate carcinoma: A recently published study conducted in mice demonstrated that the diversity of genomic changes in prostate cancer can determine the composition of immune cells within the TME.82 The authors showed that tumours derived from Trp53−/−Pten−/− tumours expressed high levels of Cxcl17, which recruited cells with immunophenotypes of monocytic myeloid-derived suppressor cells (MDSCs) and monocytes.